CliffBio
small molecule

CERVIDIL

DINOPROSTONE

Loss of exclusivity—loss of exclusivity
CompanyFerring Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameCERVIDIL
Active ingredientDINOPROSTONE
Strength10MG
Dosage formINSERT, EXTENDED RELEASE
RouteVAGINAL
ModalitySmall molecule
FDA approvalMarch 1995
Marketing statusRX

More from Ferring Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CERVIDIL patent cliff — loss of exclusivity — | CliffBio